At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Stephen Nimer, MD, from Memorial Sloan-Kettering Cancer Center, New York, NY, reviews promising epigenetic targets in cancer and explains that combining epigenetic therapies with immunotherapies may improve outcomes for patients.